Research and Markets: European Markets for Coronary Artery Bypass Graft Devices to 2013

DUBLIN–(Business Wire)–
Research and Markets
(http://www.researchandmarkets.com/research/c1e3ef/european_markets_f) has
announced the addition of the “European Markets for Coronary Artery Bypass Graft
Devices 2009″ report to their offering.

Through 2013, the market for coronary artery bypass graft (CABG) devices in
Europe will be driven largely by an increase in procedure volumes caused by
rising rates of coronary artery disease (CAD) and a growing need for repeat
revascularization procedures. Although the market will be limited by less
invasive alternative treatments, such as medical managment and percutaneous
coronary interventions, growing adoption of endoscopic vessel harvesting (EVH)
devices and anastomosis assist devices (AADs) will further support revenue
growth over the forecast period.

Questions Answered in This Report:

The global economic downturn beginning in late 2008 had a broad impact on
European CABG device markets. How have budget restrictions affected the
replacement rate of capital equipment required for CABG procedures? How long
will this impact continue to be felt in the CABG device market?

Cardiac surgeons across Europe are increasingly opting for off-pump coronary
artery bypass (OPCAB) over on-pump coronary artery bypass (ONCAB) methods. How
rapidly is this shift occuring? Will OPCAB completely replace ONCAB? For which
patient subgroups might ONCAB still have a role?

Treatment of CAD by CABG is in direct competition with interventional cardiology
methods. What clinical studies are affecting physicians’ choices? How will the
introduction and adoption of EVH and minimally invasive CABG devices affect this
rivalry?

The competitive landscape of the European CABG device market is highly dynamic.
How have companies used acquisitions to reshape or expand their portfolios? How
do the competitive landscapes of the covered countries differ?

Scope:

Regions covered: France, Germany, Italy, and the UK

Segmentation: Our analysis uses the following segmentation of the market:

* Cardiac surgery labs
* ONCAB devices
* – Disposable perfusion devices (custom perfusion pack and stand-alone:
arterial filters, cardioplegia systems, centrifugal blood pumps,
hemoconcentrators, oxygenators, reservoirs, mini-bypass circuits, and cannulae)
* – Capital equipment (cardiopulmonary bypass machines and centrifugal pump
controllers)
* OPCAB devices
* – Primary devices (stabilizers, positioners, and OPCAB kits)
* – Accessories (blowers/misters and coronary shunts)
* EVH devices
* – Saphenous vein procedures
* – Radial artery procedures
* AADs
* – Proximal (hemostatic seal systems and automated graft delivery system)
* – Distal

Market forecast features: Based on primary research with industry professionals,
we use our proprietary forecasting model to provide an in-depth examination of
current and future trends in procedure volumes, unit sales, average selling
prices, and market values over a 7-year period (20072013).

Competitive analysis: We provide a detailed analysis of the competitive
landscape in the market, as well as market shares and qualitative discussions of
the leading competitors in each market segment.

Key Topics Covered:

TABLE OF CONTENTS

LIST OF EXHIBITS

EXECUTIVE SUMMARY

METHODOLOGY

1.0 EUROPEAN CORONARY ARTERY BYPASS GRAFT DEVICE MARKET

2.0 ON-PUMP CORONARY ARTERY BYPASS DEVICE MARKET

3.0 OFF-PUMP CORONARY ARTERY BYPASS DEVICE MARKET

4.0 ENDOSCOPIC VESSEL HARVESTING DEVICE MARKET

5.0 ANASTOMOSIS ASSIST DEVICE MARKET

APPENDIX A: MRG ACRONYMS AND INITIALISMS

APPENDIX B: SUPPLEMENTAL EXHIBITS

For more information visit

http://www.researchandmarkets.com/research/c1e3ef/european_markets_f

Source: Millennium Research Group

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010

Research and Markets: Vietnam’s Infrastructure Industry’s Value for the Year Has Been Revised down To VND126trn (US$6.57bn) for 2010

DUBLIN–(Business Wire)–
Research and
Markets(http://www.researchandmarkets.com/research/fbb826/vietnam_infrastruc)
has announced the addition of the “Vietnam Infrastructure Report Q3 2010″ report
to their offering.

The Vietnam Infrastructure Report provides industry professionals and
strategists, corporate analysts, infrastructure associations, government
departments and regulatory bodies with independent forecasts and competitive
intelligence on Vietnam’s infrastructure industry.

The construction sector in Vietnam did not make as much headway this quarter as
expected, as neighbouring states started to see a turnaround thanks to stronger
economic performance. As a result the industry value for the year has been
revised down to VND126trn (US$6.57bn) for 2010. Growth over the forecast period
is now also expected to be reduced with the industry valued at VND260trn
(US$13.91bn) in 2014. This nonetheless represents a more than doubled industry
value in the space of four years.

Major infrastructure projects were thick on the ground this quarter, as both
transport and energy developments were announced. In March 2010, Vietnam’s Prime
Minister Nguyen Tan Dung, approved US$18.09bn for the construction and
development of the road system in the country. The plans include development of
over 5,000km of roads within the country. In the power sector, Vinh Tan 3 Energy
Joint Stock Company (VTEC) was approved to develop the country’s largest thermal
power project. The project, worth US$2.5bn, is expected to start in late 2011
and the plant is likely to come online in 2014- 15.

Vietnam’s business environment continues to be an issue for the country and this
quarter saw it slip one place in the regional rankings. Although its business
environment score stayed more or less static at 50.8 other countries in the Asia
Pacific region started to see stronger growth as economic conditions improved.
The country’s infrastructure market scored well; however, downside risks from
market volatility and country risk dragged down the overall score.

Corruption still remains a problem for Vietnam and is likely to continue to
impede infrastructure development until government reforms can change the
landscape. With increased foreign investment on the back of attractive growth
rates there are signs that the country is now moving in the right direction in
invoking structures to improve the business environment such as public private
partnership (PPP) regimes.

Key Topics Covered:

* SWOT Analysis
* Market Overview
* Table: Construction and Infrastructure Industry Data
* Table: Transport Infrastructure Industry Data
* Table: Ports Are The Weakest Link: Quality Of Infrastructure Global Ranking
Out Of 134 Countries
* Table: Vietnam Railway Corporations Main Targets
* Major Projects New and Ongoing Projects
* Table: Vietnam Major Transport Infrastructure Projects
* Table: Energy & Utilities Infrastructure Industry Data
* Table: The Three Levels Of Liberalising Vietnam’s Electricity Market
* Major Projects New and Ongoing Projects
* Business Environment
* Risk To Realisation Of Potential Returns
* Regional Overview
* Table: Regional Infrastructure Business Environment Ratings
* Project Finance Ratings
* Vietnam Project Finance Ratings
* Regional Overview
* Table: Design and Construction Rating
* Table: Commissioning and Operating Rating
* Table: Overall Project Finance Rating
* Macroeconomic Outlook
* Table: Vietnam – Economic Activity
* Company Monitor
* Global Overview
* Table: Design and Construction Rating
* Table: Commissioning and Operating Rating
* Table: Overall Project Finance Rating
* Table: Global Infrastructure Business Environment Ratings, April 2010
* Table: Infrastructure Business Environment Indicators

Companies Mentioned:

* Cavico Corporation
* Song Da Construction Corporation
* Vietnam Construction and Machinery Installation, Corporation (Lilama)

For more information visit

http://www.researchandmarkets.com/research/fbb826/vietnam_infrastruc.

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010

Research and Markets: European Markets for Varicose Vein Treatment Devices 2009

DUBLIN–(Business Wire)–
Research and Markets
(http://www.researchandmarkets.com/research/e37cbf/european_markets_f) has
announced the addition of the “European Markets for Varicose Vein Treatment
Devices 2009″ report to their offering.

The European varicose vein treatment device market will continue to experience
slow growth through 2013. Market dynamics are changing as the “gold standard”
varicose vein treatment procedure surgical strippingis being cannibalized by
minimally invasive alternatives. Both sclerotherapy and endovenous ablation
offer treatment with fewer painful side-effects and faster recovery than
surgical stripping. Consequently, as patients become more aware of these
alternatives, they are increasingly demanding these treatments. Although
endovenous ablation will continue to be limited by insufficient reimbursment, by
the end of the forecast period, this segment will generate more revenue than the
other treatment modalities, driving overall growth in this market.

Report Highlights:

* Gauge the impact of the economic crisis on the varicose and spider vein
treatment markets.
* Understand how reimbursement affects different segments of the varicose vein
treatment device market.
* Assess how new product and company launches affect the endovenous ablation
device market.
* Understand how adoption of foam sclerotherapy impacts the varicose vein
treatment device market.

Key Topics Covered:

1.0 EUROPEAN VARICOSE VEIN TREATMENT DEVICE MARKET

2.0 SURGICAL STRIPPING DEVICE MARKET

3.0 ENDOVENOUS ABLATION DEVICE MARKET

4.0 SCLEROTHERAPY MARKET

APPENDIX A MRG ACRONYMS AND INITIALISMS

APPENDIX B SUPPLEMENTAL EXHIBITS

Companies Mentioned:

* AngioDynamics (formerly Diomed)
* Astra Tech
* B. Braun Melsungen
* biolitec
* Celon AG medical instruments
* Codman
* Dornier MedTech
* Gamidatech
* InaVein
* INTERmedic
* Kreussler Pharma
* Laboratoires BAILLEUL
* Laboratoires PEROUSE
* LeMaitre Vascular
* MedArt
* Resinag
* STD Pharmaceutical
* Team Laser
* TELIC
* Vascular Solutions
* VNUS Medical Technologies

For more information visit

http://www.researchandmarkets.com/research/e37cbf/european_markets_f

Source: Millennium Research Group

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010

Research and Markets: An Essential Report on the Booming US Generic Drug Market

DUBLIN–(Business Wire)–
Research and Markets
(http://www.researchandmarkets.com/research/dbae84/booming_us_generic) has
announced the addition of the “Booming US Generic Drug Market” report to their
offering.

The US represents one of the world’s largest economies. The country’s per capita
income and spending are rated among the highest in the world. On the back of
rapidly growing consumer spending on branded products, total healthcare spending
of the US reached up to an estimated value of around US$ 2.5 Trillion in 2009,
which appears very high when compared to the population. The government is now
emphasizing to minimize the healthcare spending by using generics drugs and
promoting other low cost healthcare. This has created huge opportunities in the
country’s generics industry.

The US generics market is anticipated to grow at a CAGR of around 8.8% during
2010-2013, says our recent research report Booming US Generic Drug Market.
Currently, the market growth is largely fuelled by the emergence of new products
as patents of branded drugs are getting expired, and the trend is likely to
continue over the next 3-4 years also. Anticipating the future growth, big
pharma players are making deals with some generics manufactures from the Asian
countries, like India, to access their products and market them in the US. This
trend will emerge more strongly during our forecast period, providing
opportunities to the local players to widen their product portfolios.

Although several challenges, such as price erosion and litigations from branded
manufacturers, may hamper the growth, the overall growth prospects of the market
remain good. In this regard, our report provides rational analysis of various
factors which will drive the generics market in the US over the forecast period.

The report also provides extensive information on the country’s generics market,
besides discussing the emerging trends like contract manufacturing and
biogenerics. Thus, it provides valuable information to pharmaceutical & generics
companies and investors looking to enter this market. Facts and figures
regarding market size, growth, share, regulatory environment and trends in
technology development have been thoroughly analyzed in the report to provide
clients a comprehensive overview of the market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Macroeconomic Environment

4. Market Overview

5. Market Drivers

6. Industry Performance and Forecast to 2013

7. Market Potential of Generics Drugs in Key Therapies Segments

8. Regulatory Environment

9. Emerging Market Trends

10. Industry Restraints

11. Key Players

Companies Mentioned:

* Teva Pharmaceuticals
* Watson Pharmaceuticals, Inc.
* Mylan Laboratories Inc.
* Pfizer Inc.
* Sandoz Inc. (Novartis)

For more information visit

http://www.researchandmarkets.com/research/dbae84/booming_us_generic

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010